Table 1 Patient demographics and clinical variables
4 MG/KG + MTX (N = 227) | 8 MG/KG + MTX (N = 217) | Placebo + MTX (N = 232) | Total (N = 676) | P value | |
|---|---|---|---|---|---|
Age, median (Q1, Q3) | 51.0 (43.0, 62.0) | 54.0 (48.0, 61.0) | 52.5 (43.8, 61.0) | 53.0 (45.0, 61.0) | 0.031 |
Sex, n (%) | 0.176 | ||||
Female | 195 (85.9%) | 172 (79.3%) | 193 (83.2%) | 560 (82.8%) | |
Male | 32 (14.1%) | 45 (20.7%) | 39 (16.8%) | 116 (17.2%) | |
BMI, median (Q1, Q3) | 26.4 (23.4, 30.4) | 26.3 (23.4, 30.5) | 27.3 (22.6, 31.4) | 26.6 (23.2, 30.8) | 0.755 |
Disease duration, median (Q1, Q3) | 7.8 (3.8, 15.1) | 7.5 (2.8, 13.5) | 6.7 (2.4, 13.9) | 7.4 (2.9, 14.0) | 0.177 |
DAS28-ESR, median (Q1, Q3) | 6.5 (5.8, 7.2) | 6.5 (5.9, 7.1) | 6.5 (5.9, 7.2) | 6.5 (5.9, 7.2) | 0.723 |
ERN, median (Q1, Q3) | 12.4 (4.8, 23.3) | 12.5 (4.4, 23.9) | 10.4 (3.8, 21.9) | 12.0 (4.3, 23.5) | 0.354 |
JSN, median (Q1, Q3) | 6.5 (1.8, 16.6) | 6.5 (1.2, 16.6) | 5.2 (1.1, 15.0) | 6.25 (1.2, 16.0) | 0.634 |
SHP, median (Q1, Q3) | 18.8 (8.2, 43.7) | 19.6 (5.8, 42.7) | 16.2 (5.8, 37.8) | 18.1 (6.6, 41.9) | 0.404 |
HAQ, median (Q1, Q3) | 1.5 (1.0, 1.9) | 1.5 (1.3, 1.9) | 1.6 (1.1, 2.0) | 1.5 (1.1, 1.9) | 0.276 |
VAS PAIN, median (Q1, Q3) | 52.0 (39.0, 67.0) | 55.0 (42.0, 72.0) | 54.0 (44.0, 72.0) | 54.0 (41.0, 71.0) | 0.362 |
C6M ng/ml, median (Q1, Q3) | 21.8 (15.6, 30.4) | 23.1 (13.9, 33.9) | 22.1 (14.7, 33.0) | 22.5 (14.7, 32.7) | 0.802 |